Trials / Not Yet Recruiting
Not Yet RecruitingNCT07505303
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of ECC4703 as an Adjunct to Semaglutide in Adults With Obesity
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Eccogene · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ECC4703 | orally QD |
| DRUG | Placebo | orally QD |
| DRUG | Semaglutide | SC once weekly |
Timeline
- Start date
- 2026-03-13
- Primary completion
- 2026-11-20
- Completion
- 2026-11-20
- First posted
- 2026-04-01
- Last updated
- 2026-04-01
Locations
15 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07505303. Inclusion in this directory is not an endorsement.